Cost-effectiveness of empagliflozin as a treatment for heart failure with reduced ejection fraction: an analysis from the Chinese healthcare perspective

BACKGROUND: The effect of empagliflozin on the cardiovascular outcome is consistent in heart failure with reduced ejection fraction (HFrEF) patients regardless of the presence or absence of diabetes. More evidence is needed regarding the cost-effectiveness of empagliflozin in HFrEF patients. This st...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Xiaohui, Lin, Minhua, Liu, Maobai, Huang, Weiying, Nie, Xuekun, Chen, Zichun, Zheng, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9186229/
https://www.ncbi.nlm.nih.gov/pubmed/35693603
http://dx.doi.org/10.21037/jtd-22-463

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9186229/
https://www.ncbi.nlm.nih.gov/pubmed/35693603
http://dx.doi.org/10.21037/jtd-22-463

Ejemplares similares